Hepatitis Forums

Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on January 20, 2017, 10:42:23 am

Title: Near-Perfect Hep C Cure Rate for Glecaprevir/Pibrentasvir in Genotype 2s
Post by: Hep Editors on January 20, 2017, 10:42:23 am

Twelve weeks of AbbVie’s investigational daily, fixed-dose combination tablet glecaprevir/pibrentasvir, known as G/P, cured almost all people with genotype 2 of hepatitis C virus (HCV) in a recent trial, aidsmap reports.
 
Researchers from the Phase III ENDURANCE-2 trial of 302 people with genotype 2 of hep C presented findings at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston.

For more information...
https://www.hepmag.com/article/nearperfect-hep-c-cure-rate-glecaprevirpibrentasvir-genotype-2s